CLAIM #2362 · AbbVie Inc (ABBV) · 2024Q1 earnings call · Apr 26, 2024 · due Dec 31, 2024
“As I highlighted, we don't see a significant exclusionary action where Humira would be removed from a formulary going forward.”
Jeff Stewart · EVP, Chief Commercial Officer
PENDING
graded after results covering Dec 31, 2024 are reported
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2024Q1 earnings call.